Downside of Rural Living

Downside of Rural Living

Patients with cancer who live in a rural location in Australia are more likely to die than those living in…

More...
Improved Survival in Europe

Improved Survival in Europe

Findings from a retrospective observational study that included patients diagnosed with haematological malignancies from 20 European countries showed that survival…

More...
Prognostic Index for CLL

Prognostic Index for CLL

A number of biomarkers have been identified as being predictors of overall survival in chronic lymphocytic leukaemia (CLL). However, given…

More...
Real World Data on PTCL

Real World Data on PTCL

To complement retrospective analyses of clinical trials, an analysis of prognostic factors and outcomes in an unselected population-based cohort of…

More...
Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.

Healthcare Matters

  • 1
  • 2
  • 3
Prev Next

Hope for Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas (PTCL) are rare and heterogeneous lymphomas comprising numerous histologies. Given the rarity and number of these lymphomas, the tendency has been to group them as one entity. For decades they have been treated in much the same way as B-cell lymphomas using conventional chemotherapy resulting in poor long-term survival.

Read more

A Peek at AIL (Italy)

For the last 20 years, Maria Rita Grattarola has been involved with the Italian Association against leukemia-lymphoma and myeloma (AIL). Prior to joining AIL, Maria Rita was a business teacher. Initially, she volunteered for AIL and over the 20 years Maria Rita has been involved with the organisation, she has worked in many different areas. For the last 10 years, she’s been mostly responsible for organising patient seminars and patient groups.

Read more

Leukaemia & Blood Cancer New Zealand

Being a chief executive officer (CEO) comes with many responsibilities as Pru Etcheverry, CEO of Leukaemia & Blood Cancer New Zealand (LBC), can attest. “Every day is different but key responsibilities are income generation and financial management, leadership, brand building and positioning, service delivery for patients and families, and looking at organisational sustainability,” said Pru.

Read more

Latest Lymphoma News

  • Pretreated Refractory HL

    In this video, Dr. Filip Janku, from the University of Texas MD Anderson Cancer Center, discusses the findings of a trial that examined the effect of sirolimus and virinostat in patients with Hodgkin lymphoma who


    Read more...
  • Use Caution with Wikipedia

    US scientists undertook a comparison for entries in Wikipedia concerning conditions such as heart disease and lung cancer and compared them with peer-reviewed medical research.


    Read more...

What's Happening Around the World

  • A Peek at the European EWMnetwork

    This is the first in a series of articles examining the work undertaken by patient organisations to help those affected by WM.  Waldenstrom’s macroglobulinaemia (WM) is a rare, slow growing blood cancer. Approximately three in one million people are diagnosed with WM every year in the USA.

    Read more...  
  • Firefighter Sky Tower Challange Update

    In the April edition of the Node News newsletter, we focused on the work that Leukaemia & Blood Cancer New Zealand does. One of the fundraising events mentioned was the Firefighter Sky Tower Stair Challenge.

    Read more...  

Research

  • CLL and Combination Therapy

    A phase II study was undertaken to examine the effectiveness of rituximab and lenalidomide in patients with chronic lymphocytic leukaemia (CLL) who had not been treated (treatment naïve).

    Read more...  
  • Pesticides Linked to NHL

    Findings from a study undertaken by the International Agency for Research on Cancer in France show that there is a strong link between pesticides and the development of cancer including non-Hodgkin lymphoma (NHL) in the USA.

    Read more...  

 
The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.

IN THE NODE

Updates

  • CLL/SLL Survey

    The CLL/SLL Patient and Caregiver Experience Survey closes August 4. Please take a few moments to complete the appropriate survey.

  • Positive Recommendation for Ibrutinib and Idelalisib

    Ibrutinib and idelalisib have been recommended for use in the European Union by the European Medicines Agency. Read more.

  • Augment Trial

    Augment Trial is enrolling relapsed/refractory indolent NHL  in 15 countries with the hope that in combining biologic doublets certain toxicities may be avoided.

  • Idelalisib Approved in USA

    Idelalisib has been approved by the Food and Drug Administration in the USA for the treatment of three blood cancers.

THANK YOU FOR TAKING THE 2014 GLOBAL PATIENT SURVEY. The survey is now closed.